In the latest trading session, NXP Semiconductors (NXPI) closed at $205.25, marking a +1.74% move from the previous day. This change outpaced the S&P 500's 0.83% gain on the day. Meanwhile, the Dow gained 0.5%, and the Nasdaq, a tech-heavy index, added 1.38%. Shares of the chipmaker witnessed a loss of 10.07% over the previous month, trailing the performance of the Computer and Technology sector with its loss of 3.51%, and the S&P 500's loss of 2.65%. The investment community will be paying close attention to the earnings performance of NXP Semiconductors in its upcoming release. In that report, analysts expect NXP Semiconductors to post earnings of $2.98 per share. This would mark year-over-year growth of 12.88%. Meanwhile, our latest consensus estimate is calling for revenue of $3.12 billion, up 9.99% from the prior-year quarter. In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $13.93 per share and a revenue of $13.44 billion, indicating changes of +17.95% and +9.58%, respectively, from the former year. Investors should also take note of any recent adjustments to analyst estimates for NXP Semiconductors. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, we can interpret positive estimate revisions as a good sign for the business outlook. Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.8% higher. NXP Semiconductors presently features a Zacks Rank of #2 (Buy). In terms of...

Medpace (MEDP) ended the recent trading session at $389.41, demonstrating a +0.79% swing from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily gain of 0.11%. At the same time, the Dow lost 0.3%, and the tech-heavy Nasdaq gained 0.56%. The the stock of provider of outsourced clinical development services has fallen by 1.59% in the past month, lagging the Medical sector's gain of 2.86% and the S&P 500's gain of 5.06%. Market participants will be closely following the financial results of Medpace in its upcoming release. The company's earnings per share (EPS) are projected to be $2.52, reflecting a 30.57% increase from the same quarter last year. Meanwhile, our latest consensus estimate is calling for revenue of $529.73 million, up 14.94% from the prior-year quarter. For the full year, the Zacks Consensus Estimates project earnings of $11.29 per share and a revenue of $2.17 billion, demonstrating changes of +27.14% and +14.92%, respectively, from the preceding year. It's also important for investors to be aware of any recent modifications to analyst estimates for Medpace. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system. The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.53% upward. Medpace currently has a Zacks Rank of #1 (Strong Buy). In the context of valuation, Medpace is at pr...

Rithm (RITM) closed the latest trading day at $11.26, indicating a +1.26% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily gain of 0.23%. Elsewhere, the Dow lost 0.17%, while the tech-heavy Nasdaq added 0.34%. Shares of the real estate investment trust witnessed a loss of 3.81% over the previous month, trailing the performance of the Finance sector with its loss of 0.44% and the S&P 500's gain of 3.96%. The investment community will be paying close attention to the earnings performance of Rithm in its upcoming release. The company is predicted to post an EPS of $0.42, indicating a 32.26% decline compared to the equivalent quarter last year. Simultaneously, our latest consensus estimate expects the revenue to be $1.13 billion, showing an 8.86% escalation compared to the year-ago quarter. Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $1.76 per share and revenue of $4.82 billion. These totals would mark changes of -14.56% and +33.16%, respectively, from last year. Investors should also pay attention to any latest changes in analyst estimates for Rithm. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability. Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system. The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Rithm is hold...

The latest trading session saw Jabil (JBL) ending at $162.64, denoting a +1.03% adjustment from its last day's close. The stock outperformed the S&P 500, which registered a daily gain of 0.53%. Elsewhere, the Dow gained 0.38%, while the tech-heavy Nasdaq added 0.25%. Prior to today's trading, shares of the electronics manufacturer had gained 11.87% over the past month. This has outpaced the Computer and Technology sector's loss of 0.75% and the S&P 500's gain of 1.24% in that time. Market participants will be closely following the financial results of Jabil in its upcoming release. The company's earnings per share (EPS) are projected to be $1.81, reflecting a 7.74% increase from the same quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $6.41 billion, indicating a 5.25% decrease compared to the same quarter of the previous year. Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $8.78 per share and revenue of $27.35 billion. These totals would mark changes of +3.42% and -5.31%, respectively, from last year. Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Jabil. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability. Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system. The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.33% increase. J...

Social Security is an important source of money for most retirees. That's the point, as the system was set up to ensure retirees had a basic level of income on which to live. The dilemma you face is deciding when to start claiming Social Security. Here's the big reason to claim early. When can you claim Social Security? You pay into the Social Security system all of your working life. And when you stop working, you can start claiming the entitlement. The system is set up so you have a retirement age that varies based on when you were born. Some people will have a full retirement age of 65, while others will end up at 67. That is when you get your full benefit. However, you can claim as early as age 62 or wait until age 70. (Technically, you don't have to claim Social Security at all, if you don't want to.) If you claim early, your benefits are reduced for life. If you claim late, your benefits are higher for life. From a pure dollars-and-cents view, the right decision is to wait until 70 so you maximize your Social Security check. The reason why people claim at 62 That said, there's a spike in claims at 62. In fact, more people claim at 62 than at any other age. This actually makes sense in one very important way: Nobody knows when they will die. If you wait until 70 to claim Social Security, you are gambling that you will not only live to age 70 but also well beyond that age, as well. If you have significant retirement savings, that may not be a big deal for you, as you can live off of your savings until you claim. However, if you don't have material retirement savings, delaying would likely require you to continue working. But you have to consider what you are giving up by not claiming: the opportunity to stop working. You could enjoy that time doing things you love instead of earning an income so you can delay collecting Social Security. Life is what happens while you are busy doing other things The average life expectancy in the United States is around 78. On av...

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Meta Platforms (NasdaqGS:META) has signed a multi-year AI content licensing deal with News Corp to train and improve its AI models. The company is pursuing multibillion dollar, multi-year agreements with Nvidia, AMD, and Google for advanced chips and AI infrastructure. Meta is expanding its own data center footprint and creating a new applied AI engineering team to support generative AI development. Meta Platforms, the parent of Facebook, Instagram, WhatsApp, and Threads, is moving quickly to secure the data, compute power, and engineering talent it needs for generative AI. For investors watching large technology and communication platforms, this cluster of agreements and initiatives around content, chips, and infrastructure points to AI as a core priority across the business. For you, the key question is how this step up in AI resources might shape Meta's products, cost base, and competitive position over the next several years. The combination of content deals, chip partnerships, and new internal teams could influence how its apps evolve, how users interact with AI features, and how Meta compares with other large tech platforms that are also investing heavily in similar capabilities. Stay updated on the most important news stories for Meta Platforms by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Meta Platforms. NasdaqGS:META Earnings & Revenue Growth as at Mar 2026 We've flagged 0 risks for Meta Platforms. See which could impact your investment. Quick Assessment ✅ Price vs Analyst Target : At US$647.39, Meta trades about 25% below the consensus analyst price target of US$862.25. ✅ Simply Wall St Valuation : Simply Wall St estimates Meta is trading roughly 42.4% below its fair value. ❌ Recent Momentum: The share price has had a 2.1% decline over the last 30 da...

格隆汇3月10日｜今日美格智能(3268.HK)上市，无新股申购。

Rafmaster/iStock via Getty Images PagSeguro Digital Ltd. ( PAGS ) has reported Q4 '25 results . The quarter looked broadly similar to previous reads, with very little growth in payments, a lot of growth in credit, higher financial expenses from both rates and capital optimization, and better EPS than net income because the share count keeps falling. For 2026, management again expects the same broad pattern: strong credit growth, modest gross profit growth, and double-digit EPS growth, even before additional buybacks. The challenges remain a pressured payments business and increasing reliance on credit for growth. I believe these challenges are more than compensated for by a stock that still trades at about 6x my estimate of 2026 earnings while also returning a meaningful amount of capital to shareholders. I maintain a Buy rating. Q4 '25 Results The core trend in the quarter did not change from previous reads . Payments remain stable, but they are a clearly mature business, while banking keeps growing fast enough to offset that slowdown at the company level. TPV was still soft every year, down 2.5% in 4Q25, although it rose ~10% sequentially. The sequential improvement might mark the first real sign of reacceleration after a weak year. Cash-in, which is one of the better indicators of banking engagement outside credit, rose 11% to R$90.7 billion, while deposits increased ~13% to ~R$41 billion. The payments business continues to trend towards more competition, slower, if any, growth, and more pressured profitability. Payment revenues rose only 5.6% YoY. Given that TPV was down for the year, this still signals a healthy take rate. Still, on a sequential basis, TPV rebounded almost 10%, but payment revenues rose only 4.6%, indicating potential challenges. The most profitable legacy activity, merchant prepayments, was up only 1% YoY. This remains a very good business, but it no longer looks like a clear growth engine. On the other hand, we have exploding banking activity...

美国总统特朗普谈及制裁豁免，宣称：考虑让油价下跌。 油价涨势并没有我预料的那样大。 风险提示及免责条款 市场有风险，投资需谨慎。本文不构成个人投资建议，也未考虑到个别用户特殊的投资目标、财务状况或需要。用户应考虑本文中的任何意见、观点或结论是否符合其特定状况。据此投资，责任自负。

Source: Bloomberg, 5:29

In early March 2026, CVS Health and Google Cloud announced a long-term partnership to power CVS’s new Health100 platform with Gemini-based AI, secure cloud infrastructure, and interoperable data tools to create real-time, omni-channel health engagement for consumers and partners across the healthcare ecosystem. The Health100 collaboration uniquely positions Google Cloud at the center of an open, AI-enabled health data network that could deepen its enterprise footprint while testing consumer trust in high-stakes, privacy-sensitive use cases. We’ll now examine how this Health100 AI healthcare partnership may influence Alphabet’s investment narrative, especially its heavy AI infrastructure spending. Uncover the next big thing with 29 elite penny stocks that balance risk and reward. Alphabet Investment Narrative Recap To own Alphabet today, you have to believe its massive AI and cloud buildout can justify record capital spending while its ad-heavy core stays resilient. The CVS Health100 deal reinforces the main near term catalyst, which is Google Cloud’s role as AI infrastructure for large enterprises, but it does little to reduce the biggest risk: whether outsized AI data center capex will earn attractive returns if demand or pricing weakens. Among recent announcements, the AES partnership in Texas stands out alongside Health100, because both highlight Alphabet’s push to support AI growth with long term, energy efficient infrastructure. Together they underline how much of the Alphabet story now runs through Google Cloud and Gemini, where success could help offset pressure on ad margins, but also amplify the financial impact if AI investment or usage trends fall short of expectations. Yet beneath this AI optimism, investors should be aware of growing scrutiny of Alphabet’s data use and AI safety practices, which could... Read the full narrative on Alphabet (it's free!) Alphabet's narrative projects $512.6 billion revenue and $148.4 billion earnings by 2028. This require...

格隆汇3月10日｜周一（3月9日）纽约尾盘，美国10年期基准国债收益率跌3.86个基点，报4.0996%，日内交投于4.2140%-4.0919%区间，亚太盘初高开之后，持续回落。两年期美债收益率跌1.43个基点，报3.5462%，日内交投于3.6330%-3.54%区间，北京时间03:20开始一波显著的下挫行情。10年期通胀保值国债（TIPS）收益率跌1.99个基点，至1.7630%；两年期TIPS收益率涨8.53个基点，刷新日高至0.5195%，18:58开始显著下挫、20:24刷新日低至0.3353%，随后逐步回升；30年期TIPS收益率跌2.21个基点，至2.5125%。

格隆汇3月10日｜周一（3月9日）纽约尾盘，现货白银涨2.32%，报86.5074美元/盎司，亚太早盘显著下挫、日内大部分时间交投于83-85美元区间，北京时间02:16以来持续走高。COMEX白银期货涨3.07%，报86.885美元/盎司，日内交投于79.640-87.185美元区间。COMEX铜期货涨1.60%，报5.9美元/磅。现货铂金涨1.45%，现货钯金涨4.14%。

A 51-year-old man from Wales, and a 55-year-old man from Bristol - both of whom either currently or formerly held senior roles in the federation - were also arrested on the same charge.

格隆汇3月10日｜周一（3月9日）纽约尾盘，现货黄金跌0.67%，报5137.24美元/盎司，亚太盘初显著走低，06:01微涨至5198.34美元刷新日高、09:01刷新日低至5015.31美元，后续持稳于5100美元附近。COMEX黄金期货跌0.26%，报5145.50美元/盎司。

截至2026年03月09日，全球最大的黄金ETF SPDR Gold Trust持仓量为1070.71吨，较前一个交易日减少2.61吨。

原油价格在周一延续剧烈波动走势，在常规交易时段走高之后，结算后交易中受特朗普讲话影响大幅下挫。特朗普关于对伊朗战争可能不久结束的暗示也推动美元汇率走低，令黄金价格收窄了跌幅。伦敦金属交易所铝价下跌。 原油：市场剧烈波动 WTI盘后跌破90美元 原油价格周一延续剧烈波动走势，受美国总统特朗普的讲话影响，期货在结算后交易时段下跌，向每桶80美元下滑。 面对越来越大的压力以及能源价格飙升，特朗普暗示对伊朗的战争可能很快结束，称战事进程快于计划。 周一原油市场在剧烈的价格波动中震荡，交易员试图解读伊朗战争的各种动向及其对全球供应的影响。 在常规交易时段，WTI原油在约28美元的区间内波动。布伦特原油结算在99美元下方，盘中高点在119.50美元，从盘中高点到收盘价的跌幅创下历史纪录。 在亚洲交易时段的疯狂行情中，WTI期货一度飙升高达31%，因为市场担忧霍尔木兹海峡的油轮运输陷入停滞将切断对世界其他地区的供应。 但到交易时段结束时，由于全球大型经济体考虑协调释放紧急石油储备，期货回吐了大部分涨幅。WTI收盘上涨约4%。 随后，油价又在盘后交易中因特朗普的最新言论突然大幅下挫。WTI下跌逾10%，最低跌至81.19美元。 截至收盘， 4月WTI原油价格上涨4.3%，结算价为每桶94.77美元； 盘后交易中下跌超过10%； 上周期货价格创下36%的涨幅纪录； 5月布伦特原油上涨6.8%，结算价每桶98.96美元。 贵金属：特朗普讲话推动黄金收窄跌幅 特朗普暗示对伊朗战争可能很快结束后，美元汇率下跌，推动黄金价格收窄跌幅。 彭博美元指数一度下跌0.2%，令金价收复部分跌幅；原油价格在特朗普讲话之后也跌破每桶90美元。 纽约时间下午4：25，现货黄金下跌0.7%至每盎司5，135.14美元；白银价格上涨2.2%至86.42美元；钯金和铂金上涨。 基本金属：铝价下跌 铝价周一在金融市场普遍抛售中下跌，早些时候曾因中东冲突影响来自该地区的供应而触及接近四年高点。 铝价一度上涨2.8%，至每吨3，544美元，但随后转跌，因为股市下挫以及美元走强给工业金属带来压力。 由于伊朗战争影响了来自中东地区的供应，上周铝价大涨近10%，创三年来最大周涨幅。 截至伦敦市场收盘， LME期铜上涨0.7%，报12954美元/吨； LME期铝下跌1.8%，报3385.5美元/吨； LME期镍基本持平，报17...

彭博美元指数在纽约尾盘下跌，特朗普预计伊朗战争将很快结束，并考虑接管霍尔木兹海峡。特朗普讲话后，原油期货回落，美股上涨。澳元和新西兰元领涨G-10货币。 彭博美元指数周一下跌0.1%，盘中一度上涨0.7%。 七国集团财长承诺准备采取一切必要措施来支持全球能源供应，其中包括释放战略石油储备。 美国银行外汇策略师Alex Cohen表示，特朗普的评论显然引发市场反应，美元是这轮油价冲击的受益者，因此只要局势出现任何缓和迹象，都可能引发美元回落。 他补充称：“但不确定性仍在，市场将继续寻找证据，确认原油供应和航运能够开始恢复正常。” 新西兰元/美元上涨0.6%，至0.5932；澳元/美元上涨0.6%，至0.7075。 欧元/美元上涨0.1%，至1.1625；盘中一度跌至1.1507，触及去年11月24日以来的最低水平。 三菱日联金融集团的分析师建议做空欧元/美元，目标价1.13，理由包括能源市场冲击。 美元/日元微跌至157.70。 美元/加元上涨0.1%，至1.3585。 责任编辑：丁文武

格隆汇3月10日｜特朗普称与伊朗的战争已基本结束，美股三大指数集体收涨，道指涨0.5%，纳指涨1.38%，标普500指数涨0.83%。英伟达涨2.72%，谷歌A涨2.70%，苹果、特斯拉、Meta、微软至少涨0.11%。存储概念股大涨，闪迪涨超11%，西部数据涨超6%，美光科技涨超5%。芯片股上涨，阿斯麦、AMD涨超5%，英特尔、博通均涨超4%。 纳斯达克中国金龙指数收涨1.76%，热门中概股里，金山云涨19.02%，小鹏涨6.52%，B站涨6.04%，阿特斯太阳能涨4.69%，理想涨3.90%，蔚来、华住、小马智行至多涨3.35%，百胜中国、百度、汽车之家、晶科能源、唯品会至多涨2.99%，世纪互联、京东、阿里巴巴涨1.77%-1.41%，万国数据涨1.17%。

Lemon_tm/iStock via Getty Images Intro MP Materials ( MP ) has just reported final results for a year that has been nothing less than pivotal. As I wrote in my first article on the company, MP is in the process of a government-backed transformation into a company engaged in mining and production of REE magnet inputs that are critical to national security. It is the beneficiary of a landmark Department of War deal that I believe has essentially removed most downside price risk from the company, leaving its primary risk as operational execution and making it, arguably, the lowest-risk developer-stage mining company ever. Back in November, I rated the company as a Sell, primarily because it was overvalued, I didn’t see much upside potential, and we don’t really know how to value a government-backed company like this. The opportunity cost seemed high, particularly in the midst of a strong bull market. Since then, shares have been relatively flat but are currently slightly outperforming the broader market. Data by YCharts I have now upgraded my rating to a Hold. My fundamental view hasn’t changed. I still think it’s overvalued and have no idea what kind of multiple investors will put on a company like this long-term. However, since then, MP has reported strong operational results, and the world has become far riskier. The recent war in Iran seems to be only escalating right now, and holding more defensive positions has become more appealing to me. The Trump-Xi summit has the potential to drive markets in either direction and could be a positive catalyst for MP Materials without much downside potential even if talks go very well. Lastly, NdPr prices are on the rise right now, and MP is growing NdPr production at a quick pace today, giving the company a strong tailwind. Put all this together, and we have a company with some upside potential and minimal downside risks, which is well-suited for the current environment, even if it’s still overvalued today. Q4 and FY2025 Resul...

WTI原油亚洲开盘下跌10%，至每桶85.52美元 2026-03-10 06:06:55 来源： 同花顺7x24快讯 分享 文章提及标的 原油 -- 美原油 -- WTI原油亚洲开盘下跌10%，至每桶85.52美元。

普京及特朗普在两人今年的首次通话中谈到了伊朗问题。 据塔斯社援引克里姆林宫外交政策助理尤里·乌沙科夫报道，会谈持续约一小时，富有建设性且务实，“无疑将对两国在国际政治各领域的未来合作具有实际意义”。 他还表示，两国领导人还讨论了美国主导的乌克兰和俄罗斯之间的和平谈判，但没有详细说明。 特朗普下令美军攻击伊朗后，和平谈判陷入停滞。 原定于上周举行的今年第四轮会谈因伊朗战争而被推迟，双方尚未表明何时恢复会谈。 据乌沙科夫称，普京和特朗普还讨论了委内瑞拉问题。 责任编辑：丁文武

Hims & Hers Health (NYSE:HIMS) , a direct-to-consumer telehealth platform, closed Monday at $22.15, up 40.72%. The stock moved higher after announcing a collaboration with Novo Nordisk to sell branded GLP-1 weight-loss drugs. Investors are watching how the shift from compounded to FDA-approved medications affects growth and margins. Trading volume reached 168.1 million shares, about 557% above its three-month average of 25.6 million shares. Hims & Hers Health IPO'd in 2019 and has grown 126% since going public. The S&P 500 rose 0.81% to 6,794, while the Nasdaq Composite gained 1.38% to finish at 22,696. Within telehealth and online pharmacy names, Teladoc Health closed at $5.30 (+4.33%) and American Well finished at $5.55 (+1.65%), trailing Hims & Hers Health’s sharp move. Novo Nordisk dropped its patent infringement lawsuit against Hims & Hers after the two agreed to a deal under which Novo’s GLP-1 drug Ozempic would be sold on the latter’s platform, and Hims & Hers would stop marketing compounded versions of GLP-1s. HIMS stock soared 41% on the news today, while NVO inched 3% higher. Continue reading

Identity Politics Trumps Public Safety On The Chicago Transit Authority Authored by George Shay via American Greatness, The Legacy of Jesse Jackson Makes All of Us Less Safe If you ride the trains or buses in Chicago with any regularity, you don’t worry about microaggressions. You worry about being maced, mugged, or shoved onto the tracks—or, in one grotesque recent case, set on fire. That’s the lived experience of Chicagoans navigating the Chicago Transit Authority and Metra. Not academic theory. Not seminar-room sociology. Reality. So naturally, when a modest pilot program is introduced allowing the transit agencies to suspend individuals who assault conductors, spit on drivers, punch random riders, or otherwise turn public transportation into a Thunderdome audition, what does the Chicago Tribune decide is the story? Not whether the program works. Not whether it can be enforced. Not whether it deters crime. No. The story, apparently, is that it’s racist. Because roughly 90 percent of the approximately 40 individuals suspended under the program are black or Hispanic. Forty people. In a city of nearly three million. On a transit system carrying hundreds of thousands daily. That’s the scandal. The Exercise in Futility Nobody Wants to Discuss Let’s start with the obvious: The program is likely an exercise in futility. How exactly do you enforce a transit ban in 2026 Chicago? There are no ticket agents. There are no conductors policing turnstiles. Bus drivers sit behind plastic shields—cages, really—installed because too many of them were being attacked. You think a driver is going to step out from behind that barrier and say, “Excuse me, sir, our records indicate you’re under suspension”? There’s no one at the station entrances checking IDs. There’s no practical mechanism to stop someone from tapping a Ventra card or just hopping a turnstile. And if you suggest facial recognition technology? Prepare for the five-alarm firestorm about privacy, surveillance, and civil l...

Iryna Olkhova/iStock via Getty Images Palladyne AI ( PDYN ), the US defense and industrial technology firm, reported its fourth quarter and full year results after the bell on Wednesday the 4th March. The stock is up over 20%, and this is deserved. In fact, the market has a lot more catching up to do. Palladyne is an under the radar name compared to other Artificial Intelligence plays in the market. Yet despite this, the Company has quietly gone about its business, steadily building up a number of partnerships and now, as per the latest quarter, starting to build up a revenue base that will kick on in the years to come. Palladyne's 2023 pivot It would not have been misguided to write off Palladyne in 2023. Shares mulled below $1 a share, and liquidity was running dry. Then came a masterstroke pivot by the management team to move into artificial intelligence focused on military applications. This later came with a name change; "Sarcos" would become "Palladyne AI" in 2024. Not only was it on trend, it provided a renewed growth opportunity, giving a glimpse of a non-fatal end-point. Whilst the pivot may have appeared to be a last gasp move to turn the ship around, it's becoming more apparent that management was intent on the new proposition. And that software would just be the start. Launch of Palladyne Defense Palladyne went on an acquisition spree in November 2025 with three new entities coming under its wing. This culminated in the launch of Palladyne Defense. This expanded the company's capabilities within the defense industry to encompass more advanced precision manufacturing and development capabilities. A bold vertical integration move that made the offering far more compelling for government bodies. Notably, aligning the company with the Department of Defense's priorities around building US independence and new capabilities. More importantly this move represented an in-road into drone hardware capabilities. Palladyne has been working with Redcat Holdings ( RCAT...

Oil tumbled after US President Donald Trump signaled the Iran war could be ending soon, as the conflict in the Middle East upends global energy markets and sparks fresh concerns about an inflation crisis . West Texas Intermediate slumped as much as 10% to $85.52 a barrel, after a volatile session on Monday that saw oil swing in the widest range since prices briefly turned negative during the depths of the pandemic. Trump told CBS News he believed the war was “ very complete, pretty much .” Crude smashed through $100 a barrel early in the session Monday before pulling back as the world’s largest economies considered an effort to release emergency oil reserves. Still, the vital Strait of Hormuz remains effectively closed, which has led to major producers in the Persian Gulf, including Saudi Arabia, Iraq and the United Arab Emirates, curtailing output. Read More: Can Tapping Oil Reserves Tame Iran War Price Shock?: Explainer “I think you’ll see it’s going to be a short term excursion,” Trump told Republican lawmakers on Monday at his resort in Doral, Florida. Those remarks came hours after the president spoke to CBS. The intense prices swings on Monday saw WTI trade in a $38 band. Brent tumbled about $20 from its high, marking the largest-ever drop from an intraday maximum to a closing price on record. To get Bloomberg’s Energy Daily newsletter in your inbox, click here . WTI for April delivery was 7.9% lower at $ 87.28 a barrel at 6:04 a.m. in Singapore. Brent for May settlement closed 6.8% higher to settle at $98.96 a barrel on Monday after climbing as high as $119.50 in the session.